What does “labetalol selectivity” mean?
Labetalol is a beta-blocker that also blocks alpha-1 receptors. Unlike drugs that are described as “selective” for beta-1 (like metoprolol or atenolol), labetalol is generally treated as non-selective across beta receptors—meaning it blocks both beta-1 and beta-2 receptors in addition to alpha-1 blockade.
How selective is labetalol for beta-1 vs beta-2?
In clinical practice, labetalol is not considered beta-1 selective. So patients who need a beta-1 selective drug (for example, some people with conditions where beta-2 blockade can be a concern) are often started on a different agent rather than labetalol.
Why does beta-2 non-selectivity matter for patients?
Because beta-2 receptors also exist in the lungs (and in smooth muscle elsewhere), blocking beta-2 can worsen bronchospasm in some people, such as those with asthma or certain chronic lung diseases. That is one reason beta-1 selectivity is often preferred when feasible.
How is labetalol used when “selectivity” isn’t the main goal?
Labetalol’s alpha-1 blockade is the key reason it is used for blood pressure control (including acute settings such as hypertensive emergencies, depending on the context and local protocols). Its mixed alpha and beta activity can lower blood pressure effectively without relying on beta-1 selectivity alone.
What’s the bottom line?
“Labetalol selectivity” usually means it is not beta-1 selective. It blocks beta-1 and beta-2 (non-selective beta blockade) and also has alpha-1 blocking activity.